Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04647916 | Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases | active not recruiting | Phase 2 | 44 | SWOG Cancer Research NetworkNETWORK | 1 | May 6, 2026 | clinicaltrials |
| NCT05591547 | Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen(APBI RISE) | active not recruiting | Phase 2 | 91 | Sanford HealthOTHER | 1 | May 6, 2026 |
| NCT06125522 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) | active not recruiting | Phase 1 / Phase 2 | 11 | PfizerINDUSTRY | 4 | May 6, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT06727773 | Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer | recruiting | Phase 2 | 90 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06845319 | NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients(NeoCARD) | recruiting | Phase 2 | 43 | Medical University of South CarolinaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07220135 | Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer(NeoTHERa) | recruiting | Phase 2 | 100 | University of Kansas Medical CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05716516 | STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)(ESTHER) | recruiting | Phase 2 | 36 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07354919 | Axelopran for Advanced Cancer in Patients Receiving Opioids(AxeCan) | recruiting | Phase 2 | 34 | HealthPartners InstituteOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04305834 | Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. | recruiting | Phase 2 | 43 | City of Hope Medical CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04434040 | Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | recruiting | Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT01245712 | Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer | active not recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07285993 | Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET | not yet recruiting | Phase 2 | 15 | Randy YehOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05608252 | VS-6766+Abema+Fulv in Met HR+/HER- BC | recruiting | Phase 1 / Phase 2 | 63 | Adrienne G. WaksOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07539753 | Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases | not yet recruiting | Phase 2 | 46 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07560124 | A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 286 | AkesoINDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04468061 | Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | recruiting | Phase 2 | 110 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06172127 | PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer(DEMETHER) | active not recruiting | Phase 2 | 165 | MedSIROTHER | 5 | Apr 29, 2026 | clinicaltrials |
| NCT03789110 | NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer | active not recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05645380 | Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC(NeoTRACT) | active not recruiting | Phase 2 | 139 | University of Kansas Medical CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07276880 | Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer(P-RAD(+)TN-DCT) | recruiting | Phase 2 | 32 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT02734290 | Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 29 | Providence Health & ServicesOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT04373031 | Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer | active not recruiting | Phase 2 | 12 | Providence Health & ServicesOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05982093 | Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer(SOLTI-2104) | recruiting | Phase 2 | 96 | SOLTI Breast Cancer Research GroupOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06434064 | Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer | recruiting | Phase 2 | 30 | Roswell Park Cancer InstituteOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07443943 | A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial(AIMSS-RPS) | recruiting | Phase 2 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03756298 | Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | active not recruiting | Phase 2 | 284 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06062810 | Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms(Drugs-SNPs) | active not recruiting | Phase 2 / Phase 3 | 600 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07494448 | Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer(JAZMINE) | not yet recruiting | Phase 1 / Phase 2 | 24 | MedSIROTHER | 0 | Apr 23, 2026 | clinicaltrials |
| NCT04837820 | The Effect of Acupuncture on Cancer-Related Cognitive Difficulties | active not recruiting | Phase 2 | 270 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05455619 | Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer(Amelia-1) | recruiting | Phase 1 / Phase 2 | 52 | SynDevRx, Inc.INDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07069595 | PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease(PREDICT-RD) | recruiting | Phase 2 | 78 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07123649 | Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study(I-MAMMO) | recruiting | Phase 2 | 364 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07378306 | FMD and Neoadjuvant Chemo-immunotherapy in TNBC(FACT-TN) | recruiting | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT03366844 | Breast Cancer Study of Preoperative Pembrolizumab + Radiation | active not recruiting | Phase 1 / Phase 2 | 66 | Stephen ShiaoOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT03820141 | Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer(DTP) | active not recruiting | Phase 2 | 51 | The Methodist Hospital Research InstituteOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05491226 | Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation | recruiting | Phase 2 | 35 | Stephen ShiaoOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06134375 | A Study of Tetrathiomolybdate (TM) Plus Capecitabine | recruiting | Phase 1 / Phase 2 | 204 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07015853 | ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation | not yet recruiting | Phase 2 | 34 | Stephen ShiaoOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07540533 | A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer(2025-370) | recruiting | Phase 2 | 92 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 20, 2026 | clinicaltrials |
| NCT02326974 | T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA | active not recruiting | Phase 2 | 164 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02917421 | Accelerated Radiation Therapy (ART) to the Breast and Nodal Stations(ART) | active not recruiting | Phase 1 / Phase 2 | 88 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03971409 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer(InCITe) | active not recruiting | Phase 2 | 145 | Laura Huppert, MD, BAOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06042569 | Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial | recruiting | Phase 2 | 174 | City of Hope Medical CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06427226 | Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity | recruiting | Phase 2 | 46 | Tanta UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06492759 | High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer | recruiting | Phase 2 | 29 | Emory UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07527806 | Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging | not yet recruiting | Phase 2 | 156 | Peking University Cancer Hospital & InstituteOTHER | 0 | Apr 17, 2026 | clinicaltrials |
| NCT03377387 | Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 34 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05749588 | FUSCC Refractory TNBC Platform Study (FUTURE2.0) | recruiting | Phase 2 | 120 | Fudan UniversityOTHER | 1 | Apr 16, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 6, 2026source: clinicaltrials